Identifícate
Grupos
Investigadores/as
Resultados
HOSPITAL UNIVERSITARIO RUBER
Departamento
Université Catholique de Louvain
Louvain-la-Neuve, Bélgica
Estás en
Colaboraciones
Université Catholique de Louvain
Publicaciones en colaboración con investigadores/as de Université Catholique de Louvain (2)
2022
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Journal of Clinical Oncology, Vol. 32
2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 7, pp. 904-916
Contactar
Aviso Legal
Ayuda
translate
es
arrow_drop_down
translate
es
arrow_drop_down
ca
eu
gl
en
fr
de